行情

RTRX

RTRX

Retrophin
NASDAQ

实时行情|Nasdaq Last Sale

15.63
+0.50
+3.30%
盘后: 15.63 0 0.00% 16:00 04/08 EDT
开盘
15.36
昨收
15.13
最高
15.93
最低
15.01
成交量
42.31万
成交额
--
52周最高
23.26
52周最低
8.98
市值
6.74亿
市盈率(TTM)
-4.5111
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测RTRX价格均价为28.57,最高价位35.00,最低价为19.00。

EPS

RTRX 新闻

更多
  • Do Options Traders Know Something About Retrophin (RTRX) Stock We Don't?
  • Zacks · 03/18 14:01
  • Retrophin Announces Enrollment of First 190 Patients in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
  • GlobeNewswire · 03/09 13:00
  • Edited Transcript of RTRX earnings conference call or presentation 24-Feb-20 9:30pm GMT
  • Thomson Reuters StreetEvents · 03/08 21:09
  • Retrophin Recognizes Rare Disease Day 2020 and the Importance of Working Together Toward More Equitable Access to Care
  • GlobeNewswire · 02/28 13:00

所属板块

生物技术和医学研究
+3.08%
制药与医学研究
+2.83%

热门股票

代码
价格
涨跌幅

RTRX 简况

Retrophin, Inc. is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. Its Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. Its Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.
展开

微牛提供Retrophin Inc(NASDAQ-RTRX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的RTRX股票新闻,以帮助您做出投资决策。